Bioelectronic Medicine / Neuromodulation / Medical Devices
Strategic Profile
Expansion into new indications and integration of acquired products is expected to drive broad, long-term demand growth and greater operating leverage, with emphasis on digital health, recurring revenue models, and strategic investments positioned for scalable margin improvement. The portfolio combines prescription neuromodulation therapies for chronic pain and headache-related conditions with consumer-facing wellness and performance products.
Cyborg Score Rationale
In 2024, electroCore's revenue was $25.18 million, an increase of 57.09% compared to the previous year. Strong revenue growth and analyst optimism are offset by slow market penetration, regulatory hurdles, persistent operating losses, rising digital health competition, and potential patent issues that threaten product differentiation.
Top Insights
Revenue grew 57% YoY to $25.18M in 2024 with improving loss profile (-$11.89M, down 36.89%)
Analyst consensus is "Strong Buy" with 12-month price target of $22.0, implying 303% upside from current levels
Diversified product portfolio spanning gammaCore (prescription migraine/headache treatment), Truvaga wellness devices, and TAC-STIM for human performance enhancement
Early-stage commercial company pursuing regulatory expansion and new indications for significant TAM expansion in pain/neuromodulation markets
Named Competitors
Migraine and Chronic Pain Management — Established competitors in prescription pain management
Wellness Neuromodulation — Emerging competitors in non-invasive health optimization
Recent Developments
(January 2026) Partnership with Acacia Clinics and Vagus Nerve Society for research initiative